The adoption and integration of biomarkers into research and drug development is predicted to be a key trend in life sciences over the next decade, leading to shorter and less costly clinical trials and safer and more efficacious drugs.
Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, together with its joint venture partner MDS Sciex, a division of MDS Inc. (NYSE:MDZ, TSX:MDS), today announced the introduction of the Applied Biosystems/MDS SCIEX 4800 MALDI TOF/TOF™ Analyzer, the most sensitive MALDI TOF/TOF mass spectrometer for identifying and quantifying protein biomarkers. The new instrument achieves a ten-fold increase in sensitivity over existing commercially available systems and offers unparalleled experimental efficiency using powerful, automated workflows, making it an ideal solution for protein biomarker discovery.
The 4800 MALDI TOF/TOF™ Analyzer combines the Applied Biosystems/MDS SCIEX joint venture’s breakthrough TOF/TOF™ optics technology with the novel OptiBeam™ on-axis laser, which increases the number of ions directed into the ion path to achieve the dramatic increase in sensitivity. Additionally, the enhanced QuanTIS™ precursor ion allows users to more specifically isolate the precursor ions designated for MS/MS, thus achieving more accurate and easier-to-interpret results. Proprietary iTRAQ™ and ICAT® reagents, which are fully compatible with the new 4800 MALDI TOF/TOF™ Analyzer, further enable biomarker discovery by permitting relative and absolute protein quantitation. The increased sensitivity and expanded dynamic range of the analyzer yields high-confidence protein identifications, enables multiplex studies with the use of the iTRAQ™ reagents, and enables true results-dependent analysis results with or without tagging chemistry, such as ICAT® reagents.
“The use of protein biomarkers has the potential to radically change drug discovery and development over the next decade,” said Catherine M. Burzik, President of Applied Biosystems. “Whether clinical researchers are using biomarkers to investigate a drug's physiological path of action, or to investigate whether an individual has a particular disease, how severe the disease is, and how it changes over time, biomarkers hold the key to the development of more targeted, effective therapies for individuals.”
In addition, the system is enabled for support of LC-MALDI workflows using GPS Explorer Software with the industry standard Mascot® database search engine. GPS Explorer Software supports automated, intelligent analysis of complex samples by focusing on collecting data with the highest relevance, for cleaner, less redundant data. The new Opti-TOF™ microtitre sample plates are disposable, large format plates that maximize throughput and minimize sample carry over, while providing convenient sample handling and archiving.
“This new instrument provides our customers with the most direct route to answering relevant biological questions,” said Andy Boorn, President of MDS Sciex. “The goal of the Applied Biosystems/MDS SCIEX joint venture is to enable better protein identification and quantification in complex biological samples for proteomics applications ranging from biomarker discovery to pathway elucidation and systems biology experiments. The 4800 analyzer is an ideal solution for high-productivity LC-MALDI and expression-dependent biomarker discovery experiments.”
With the introduction of the 4800 MALDI TOF/TOF™ Analyzer, the Applied Biosystems/MDS SCIEX joint venture expands its offering in MALDI tandem TOF technology and its overall proteomics mass spectrometry portfolio. The MALDI tandem TOF family includes the 4700 Proteomics Analyzer with TOF/TOF™ Optics, and the proteomics mass spectrometry portfolio includes the 3200 and 4000 Q TRAP® LC/MS/MS Systems and the QSTAR® XL LC/MS/MS System. The new analyzer will be on display during the 53rd Annual meeting of the American Society of Mass Spectrometry in San Antonio, TX, U.S.A., June 6-9, 2005, and is available for immediate shipment.
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com , or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/ .
About MDS Sciex and MDS Inc.
MDS Sciex is the analytical instrumentation and technology solutions division of MDS Inc. At MDS Inc. (TSX: MDS; NYSE: MDZ), our 9,000 highly skilled people provide services and products, which enable health sciences organizations to enhance the well being of people around the world. We focus on helping discover and test new drugs, assisting doctors to diagnose and treat patients and preventing the spread of disease. Find out more about MDS Inc., at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.
Copyright© 2005. Applera Corporation and MDS Inc. All rights reserved. Applera, Celera Diagnostics and iTRAQ are trademarks and Applied Biosystems and Celera are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
Explorer, MALDI TOF/TOF, OptiBeam, Opti-TOF, QuanTIS, RDA and TOF/TOF are trademarks of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc.
ICAT is a registered trademark of the University of Washington and is exclusively licensed to the Applied Biosystems Group of Applera Corporation.
All other trademarks are the sole property of their respective owners.
For research use only. Not for use in diagnostic procedures.
Copyright© 2005. Applera Corporation and MDS Inc. All rights reserved. Information subject to change without notice.